These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 8558198

  • 1. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
    Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM.
    J Clin Oncol; 1996 Jan; 14(1):196-203. PubMed ID: 8558198
    [Abstract] [Full Text] [Related]

  • 2. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J, Talpaz M, O'Brien S, Rios MB, Majlis A, Keating M, Freireich EJ, Kantarjian H.
    J Clin Oncol; 1998 Oct; 16(10):3279-85. PubMed ID: 9779702
    [Abstract] [Full Text] [Related]

  • 3. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J.
    Cancer; 2003 Nov 01; 98(9):1905-11. PubMed ID: 14584073
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia.
    Przepiorka D, Thomas ED.
    Bone Marrow Transplant; 1988 Mar 01; 3(2):113-9. PubMed ID: 3048475
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.
    Clin Cancer Res; 2002 Jul 01; 8(7):2177-87. PubMed ID: 12114418
    [Abstract] [Full Text] [Related]

  • 6. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):23-6. PubMed ID: 15946504
    [Abstract] [Full Text] [Related]

  • 7. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
    O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM.
    Leukemia; 2003 Mar 01; 17(3):481-7. PubMed ID: 12646934
    [Abstract] [Full Text] [Related]

  • 8. Serial cytogenetic studies in allografted patients with chronic myeloid leukemia.
    Bilhou-Nabera C, Bernard P, Marit G, Viard F, Gharbi MJ, Wen Z, Lacombe F, Broustet A, Reiffers J.
    Bone Marrow Transplant; 1992 Apr 01; 9(4):263-8. PubMed ID: 1600414
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M.
    Cancer; 2002 Oct 15; 95(8):1673-84. PubMed ID: 12365015
    [Abstract] [Full Text] [Related]

  • 13. Karyotype at relapse following allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Shah NK, Wagner J, Santos G, Griffin CA.
    Cancer Genet Cytogenet; 1992 Jul 15; 61(2):183-92. PubMed ID: 1638501
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Chronic myeloid leukemia. Karyotype changes].
    Rojas-Atencio A, Pineda-Del Villar L, Avila-León E, González-Ferrer S, Prieto-Carrasquero M, Soto M, González R.
    Invest Clin; 1996 Sep 15; 37(3):167-75. PubMed ID: 8983354
    [Abstract] [Full Text] [Related]

  • 16. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M.
    Cancer; 2003 Oct 01; 98(7):1430-7. PubMed ID: 14508830
    [Abstract] [Full Text] [Related]

  • 17. Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia.
    Chase A, Pickard J, Szydlo R, Coulthard S, Goldman JM, Cross NC.
    Genes Chromosomes Cancer; 2000 Mar 01; 27(3):278-84. PubMed ID: 10679917
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.